Human Growth Hormone (TransCon hGH CT-302) – NOW ENROLLING  

fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children with Growth Hormone Deficiency (GHD) (TransCon hGH CT-302)

Protocol, purpose and description: A 26 week trial of TransCon hGH, a long-acting growth hormone product, administered once-a-week. Approximately 150 children (males and females) with growth hormone deficiency (GHD) will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Canada, Australia, and New Zealand.

CHKD physicians involved: Kent Reifschneider, MD, Marta Satin-Smith, MD, Eric Gyuricsko, MD

Learn more about this study.

Or  contact Erika Paradiso at (757) 668-7732 or Erika.Paradiso@chkd.org